Interleukin-6 and tumor necrosis factor a levels after bisphosphonates treatment in vitro and in patients with malignancy

Bone

Volumn 18, Issue 2, 1996, Pages 133-139

  Sauty, A ^a   Pecherstorfer, M ^b   Zimmer Roth, I ^b   Fioroni, P ^a   Juillerat, L ^a   Markert, M ^a   Ludwig, H ^b   Leuenberger, P ^a   Burckhardt, P ^a   Thiébaud, Daniel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

Acute phase reaction; Bisphosphonates; C reactive protein; Interleukin 1; Interleukin 6; TNF

Indexed keywords

ALBUMIN; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; CLODRONIC ACID; IBANDRONIC ACID; INTERLEUKIN 1; INTERLEUKIN 6; PAMIDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY TEMPERATURE; CALCIUM BLOOD LEVEL; CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; FEVER; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MONOCYTE; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; BONE RESORPTION; CLODRONIC ACID; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029986140     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/8756-3282(95)00448-3     Document Type: Article

References (39)

1. Adami, A., Bhalla, A. K., Dorizzi, R., Montesanti, F., Rosini, S., Salvagno, G., and Lo Cascio, V. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326-331; 1987.
2. Bijvoet, O. L. M., Frijlink, W. B., Jie, K., van der Linden, H., Meijer, C. J. L. M., Meijer, Mulder H., van Paassen, H. C., Reitsma, P. H., de Velde, J., de Vries, E., and van der Wey, J. P. APD in Paget's disease of bone: role of the mononuclear phagocyte system? Arthritis Rheum 23:1193-1204; 1980.
3. Body, J.-J. Bone metastases and tumor-induced hypercalcemia. Curr Opin Oncol 4:624-631; 1992.
4. Beutler, B., and Cerami, A. Cachectin: more than a tumor necrosis factor. N Engl J Med 316:379-385; 1987.
5. Burger, E. H., van der Meer, J. W. M., van de Gevel, J. S., Gribnau, J. C., Thesingh, C. W., and van Furth, R. In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes. J Exp Med 156:1504-1614; 1982.
6. Castell, J. V., Gómez-Lechón, M. J., David, M., Andus, T., Geiger, T., Trullenque, R., Fabra, R., and Heinrich, P. C. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 242:237-239; 1989.
7. Cecchini, M. G., and Fleisch, H. Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 5:1019-1027; 1990.
8. Dinarello, C. A. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med 311:1413-1418; 1984.
9. Dinarello, C. A., Cannon, J. G., Wolff, S. M., Bernheim, H. A., Beutler, B., Cerami, A., Figari, I. S., Palladino, M. A. Jr., and O'Connor, J. V. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163:1433-1450; 1986.
10. Dinarello, C. A. Interleukin-1 and its biologically related cytokines. Adv Immunol 44:153-205; 1989.
11. Eveq̂uoz, V., Trechsel, U., and Fleisch, H. Effect of bisphosphonates on production of interleukin 1-like activity by macrophages and its effect on rabbit chondrocytes. Bone 6:439-444; 1985.
12. Fitton, A., and McTavish, D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289-318; 1991.
13. Fleisch, H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919-944; 1991.
14. Gallacher, S. J., Ralston, S. H., Patel, U., and Boyle, I. T. Side-effects of pamidronate. Lancet ii:42-43; 1989.
15. Ganter, U., Arcone, R., Toniatti, C., Morrone, G., and Ciliberto, G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 8:3773-3779; 1989.
16. Gauldie, J., Richards, C., Harnish, D., Lansdorp, P., and Baumann, H. Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84:7251-7255; 1987.
17. Harinck, H. I. J., Papapoulos, S. E., Blanksma, H. J., Moolenaar, A. J., Vermeij, P., and Bijvoet, O. L. M. Paget's disease of bone: early and late responses to three different modes of treatment with aminohyxdroxypropylidene bisphosphonate (APD). Br Med J 295:1301-1305; 1987.
18. Helle, M., Brakenhoff, J. P. J., De Groot, E. R., and Aarden, L. A. Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol 18:957-959; 1988.
19. Hirano, T., Akira, S., Taga, T., and Kishimoto, T. Biological and clinical aspects of interleukin 6. Immunol Today 11:443-448; 1990.
20. Hopkins, S. J., and Humphreys, M. Simple, sensitive and specific bioassay of interleukin-1. J Immunol Mem 120:271-276; 1989.
21. Houssiau, F. A., Devogelaer, J.-P., Van Damme, J., Nagant de Deuxchaisnes, C., and Van Snick, J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31:784-788; 1988.
22. Hughes, D. E., Mian, M., Guilland-Cumming, D. F., and Russell, R. G. G. The cellular mechanism of action of bisphosphonates. Drugs Exp Clin Res 17:109-114; 1991.
23. Leyvraz, S., Hess, U., Flesch, G., Bauer, J., Hauffe, S., Ford, J. M., and Burckhardt, P. J Natl Cancer Inst 84:788-792; 1992.
24. Macarol, V., and Frauenfelder, F. T. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118:220-224; 1994.
25. Mönkkönen, J., Pennanen, N., Lapinjoki, S., and Urtti, A. Clodronate (dichloromethylene bisphosphonate) inhibits LPS-stimulated IL-6 and TNF production by RAW 264 cells. Life Sci 54:229-234; 1994.
26. Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., and Fleisch, H. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011; 1991.
27. O'Rourke, N. P., McCloskey, E. V., Rosini, S., Coleman, R. E., and Kanis, J. A. Treatment of malignant hypercalcemia with aminohexane bisphosphonate (neridronate). Br J Cancer 69:914-917; 1994.
28. Papapoulos, S. E. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med 95(suppl. 5A):48S-52S; 1993.
29. Pennanen, N., Nissinen, T., Lapinjoki, S., Urtti, A., and Mönkkönen, J. The effect of liposome-encapsulated and free bisphosphonates on IL-1β, IL-6 and TNFα secretion from macrophages. Bone Miner 25(suppl. 1):S67; 1994.
30. Perlmutter, D. H., Dinarello, C. A., Punsal, P. I., and Colten, H. R. Cachectin/ tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest 78:1349-1354; 1986.
31. Pioli, G., Hughes, D. E., Mian, A., Aarden, L., Meager, A., Chapman, K., and Russell, R. G. G. Bisphosphonates stimulate the production of cytokines by human peripheral blood mononuclear cells in vitro. Calcif Tissue Int 46(suppl. 2):A54; 1990.
32. Schweitzer, D. H., Oostendorp-Van de Ruit, M., Van der Pluijm, G., Löwik, C. W. G. M., and Papapoulos, S. E. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 10:956-962; 1995.
33. Siris, E. Bisphosphonates and iritis. Lancet ii:436-437; 1993.
34. Stevenson, P. H., and Stevenson, J. R. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int 38:227-233; 1986.
35. Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., and Soørensen, O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271; 1990.
36. Thiébaud, D., Jaeger, P., Gobelet, C., Jacquet, A. F., and Burckhardt, P. A single Infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am J Med 85:207-212; 1988.
37. de Vries, E., van der Weij, J. P., van der Veen, C. J. P., van Paassen, H. C., Jager, M. J., Sleeboom, H. P., Bijvoet, O. L. M., and Cats, A. In vitro effect of (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation. Immunology 47:157-163; 1982.
38. Wakefield, D., and Lloyd, A. R. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine 4:1-5; 1992.
39. Wüster, C., Schöter, K. H., Thiébaud, D., Manegold, C., Krahl, D., Clemens, M. R., Ghielmini, M., Jaeger, P., and Scharla, S. H. Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Miner 22:77-85; 1993.